

Please Direct All Correspondence to Customer Number **45311**

TRANSMITTAL LETTER
INFORMATION DISCLOSURE STATEMENT


Applicant : Whitehead et al.
App. No : 10/719,547
Filed : November 21, 2003
For : DEVELOPMENT OF MUTATIONS
USEFUL FOR ATTENUATING DENGUE
VIRUSES AND CHIMERIC DENGUE
VIRUSES
Examiner : Scheiner, Laurie A.
Art Unit : 1648

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

May 18, 2005

(Date)


Nancy W. Vensko, Reg. No. 36,298

Mail Stop Amendment

Commissioner for Patents


P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing Seven (7) references.
 - (X) Enclosing Seven (7) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Nancy W. Vensko
Registration No. 36,298
Attorney of Record
Customer No. 45,311
(805) 547-5580

PA-125

1705337:cbm
051005

INFORMATION DISCLOSURE STATEMENT

Applicant : Whitehead et al.
App. No : 10/719,547
Filed : November 21, 2003
For : DEVELOPMENT OF MUTATIONS
USEFUL FOR ATTENUATING DENGUE
VIRUSES AND CHIMERIC DENGUE
VIRUSES
Examiner : Scheiner, Laurie A.
Art Unit : 1648

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing Seven (7) references to be considered by the Examiner. Also enclosed are Seven (7) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 5/18/05

By: 
Nancy W. Vensko
Registration No. 36,298
Attorney of Record
Customer No. 45,311
(805) 547-5580



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/719,547
Filing Date	November 21, 2003
First Named Inventor	Whitehead, Stephen S.
Art Unit	1648
Examiner	Scheiner, Laurie A.
Attorney Docket No.	NIH214.001C1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	1	WO 00/57907 A1	10/05/2000	Whitehead et al.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	2	DATABASE NCBI 3 January 2001, XP0021317338 retrieved from NCBI accession no. GI:12018173; Database accession no. AF 326827	
	3	DATABASE NCBI 3 January 2001, XP002317339 retrieved from NCBI accession no. GI:2018169; Database accession no. AF326825	
	4	Durbin, Anna P. et al., "A recombinant live attenuated dengue virus type 4 vaccine candidate is highly attenuated and immunogenic in humans," Clinical Infectious Diseases, vol. 31, no. 1, July 2000, page 223	
	5	Hanley, Kathryn A. et al., "Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes," Journal of Virology, vol. 76, no. 2, January 2002, pages 525-531	
	6	Lai, C. J. et al., "Evaluation of molecular strategies to develop a live dengue vaccine," Clinical and Diagnostic Virology, vol. 10, no. 2/3, 1998, pages 173-179	
	7	Marchette, N. J. et al., "Preparation of an attenuated dengue 4 (341750 carib) virus vaccine. I. pre-clinical studies," American Journal of Tropical Medicine & Hygiene, Lawrence, KS, US, vol. 43, no. 2, August 1990, pages 212-218	

1704176:cbm
050905

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.